Actinium Pharmaceuticals, Inc. (ATNM)
| Market Cap | 311.15M |
| Revenue (ttm) | 1.05M |
| Net Income (ttm) | -30.38M |
| Shares Out | 25.48M |
| EPS (ttm) | -1.30 |
| PE Ratio | n/a |
| Forward PE | 6.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 219,770 |
| Open | 11.75 |
| Previous Close | 11.93 |
| Day's Range | 11.75 - 12.25 |
| 52-Week Range | 4.41 - 15.12 |
| Beta | 0.49 |
| Analysts | Buy |
| Price Target | 31.82 (+160.61%) |
| Earnings Date | Feb 13, 2023 |
About ATNM
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers c... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for ATNM stock is "Buy." The 12-month stock price forecast is $31.82, which is an increase of 160.61% from the latest price.
News
Actinium Pharmaceuticals, Inc. to Present at the 3rd Annual B. Riley Securities Oncology Conference
NEW YORK , Jan. 17, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that th...
Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem Meetings
NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that dat...
Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASH
- 59% 1-year overall survival and 32% 2-year overall survival in patients with prior Venetoclax treatment - 52% 1-year overall survival and 19% 2-year overall survival in patients with a TP53 mutati...
Actinium Pharmaceuticals, Inc. Announces Research Collaboration with Columbia University to Study Actimab-A in AML Patients Following Transplant of Engineered Hematopoietic Stem Cells Gene Edited to be CD33 Negative
- Collaboration builds on the groundbreaking research of Columbia University oncologist Dr. Siddhartha Mukherjee that uses gene-editing to remove the CD33 surface protein from hematopoietic stem cells...
Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial
53% 1-year Overall Survival and 32% 2-year Overall Survival are approximately double outcomes with current approaches Patients on study received a median of 2 lines of prior therapy with 57% receiving...
Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Commercialization
-Caroline joins Actinium from Novartis where she served as Portfolio General Manager, US Oncology-Proven commercial leadership experience spans hematology, oncology and rare diseases at Novartis, Glax...
Actinium's stock jumps 22% on new data for its acute myeloid leukemia therapy
Shares of Actinium Pharmaceuticals Inc. ATNM, +24.20% were up 22.8% in trading on Monday after the company met the primary endpoint in a Phase 3 clinical trial for its investigational treatment for re...
Actinium (ATNM) Stock Pops on Positive Trial Results
Actinium Pharmaceuticals (NYSEMKT: ATNM) stock is gaining on Monday after posting positive results from a Phase 3 clinical trial. The point of this clinical trial was to determine the effectiveness o...
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
- Iomab-B met the primary endpoint of durable complete remission of 6-months following initial complete remission after HCT with a p-value of
Actinium Expands Clinical Leadership Team to Support Key Development Programs for Iomab-B and Actimab-A
Key hires with proven expertise and track records in Bone Marrow Transplant, Acute Myeloid Leukemia, Radiation Sciences and Clinical Operations position Actinium well to drive key clinical programs fo...
Actinium (ATNM) Stock Jumps 8.6%: Will It Continue to Soar?
Actinium (ATNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro...
Actinium Pharmaceuticals to Participate in the 2022 Bio-Europe Conference
NEW YORK , Oct. 26, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, today announced that it ...
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Jenny Hsieh joins Actinium as Chief Strategy Officer from Gilead Sciences, following its acquisition of Immunomedics Sunitha Lakshminarayanan, Senior Vice President, Head of CMC and Product Developmen...
Actinium to Present at the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference
NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, today announced that it...
IBA and SCK CEN launch Pantera, a joint-venture to produce actinium-225
Louvain-La-Neuve, Belgium, 22 September 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and the Belgian Nuclear Research Centre SCK CEN today an...
Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones
On track to report topline data from the Pivotal Phase 3 SIERRA trial for Iomab-B in Q4 2022 Overall survival data from the Actimab-A CLAG-M combination trial expected in Q4 2022 Additional updates on...
Actinium Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
NEW YORK , Sept. 8, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet ...
Actinium Pharmaceuticals, Inc. Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means but 100% of Patients who Received Iomab-B, Including Crossover Patients, in the Phase 3 SIERRA Trial Successfully Engrafted
- Data from completed Iomab-B pivotal Phase 3 SIERRA trial demonstrate the potential of Iomab-B in enabling successful BMT in patients who cannot typically be transplanted - 5x greater magnitude of I...
Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
- Updated Phase 3 SIERRA data to be presented in an oral presentation by Boglarka Gyurkocza, M.D., SIERRA trial investigator from Memorial Sloan Kettering Cancer Center - Iomab-B to be featured in a C...
Actinium (ATNM) Up on Commercialization Deal With Immedica
Actinium (ATNM) out-licenses exclusive rights to Iomab-B, an antibody radiation conjugate for facilitating bone-marrow transplant, to Immedica in Europe, the Middle East and North African countries.
Biotech Stocks News: What's Going on With LIXT, PTE, QLGN and ATNM Stocks Today?
Biotech stocks are up today amid an influx of positive news. Here's what investors need to know as these small companies skyrocket.
Why Actinium Pharmaceuticals Stock Is Surging
Actinium Pharmaceuticals Inc (AMEX:ATNM) shares are trading higher Tuesday morning after the company announced it entered into a license and supply agreement with Immedica Pharma for Iomab-B. Actiniu...
Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa
-Potential for up to $452 million in milestone payments with royalties in the mid-twenty percent range -Actinium receives $35 million upfront payment -Immedica obtains exclusive rights to Iomab-B in E...
Actinium Pharmaceuticals Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR
- Data show enhanced antitumor effects and improved survival were observed in a preclinical NSCLC model compared to a naked HER3 antibody - HER3 targeted radiotherapy represents a novel therapeutic st...
Actinium Pharmaceuticals Presents Preclinical Data at AACR Showing HER3 Targeted Radiotherapy Combined with the CD47 Immunotherapy Magrolimab Increases the Anti-tumor Effect
Data further expand Actinium's leadership in combining targeted radiotherapy with CD47 immunotherapy in solid tumors and blood cancers Significant increase in tumor control with the HER3 ARC magrolima...